Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial
Authors
Bottomley, A.Kicinski, M.
Long, G. V.
Mandala, M.
Atkinson, V. G.
Blank, C. U.
Haydon, A. M.
Dalle, S.
Khattak, A.
Carlino, M. S.
Meshcheryakov, A.
Sandhu, S. K.
Sarda, S. S.
Coens, C.
Suciu, S.
Grebennik, D.
Krepler, C.
Lorigan, Paul C
Robert, C.
Eggermont, A. M. M.
Affiliation
Dept Of Oncology, University College London Hospitals NHS Foundation Trust, UCL Cancer Institute and CRUK Lung Cancer Centre of Excellence, NW1 2PG - LondonIssue Date
2022
Metadata
Show full item recordCitation
Bottomley A, Kicinski M, Long GV, Mandala M, Atkinson VG, Blank CU, et al. Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial. Annals of Oncology. 2022 Sep;33(7):S1410-S1. PubMed PMID: WOS:000866211602453.Journal
Annals of OncologyDOI
10.1016/annonc/annonc1089Additional Links
https://dx.doi.org/10.1016/annonc/annonc1089Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/annonc/annonc1089